Skip to main content
Erschienen in: Clinical and Experimental Medicine 8/2023

28.10.2023 | Review

Behçet’s syndrome: recent advances to aid diagnosis

verfasst von: Tayfun Hilmi Akbaba, Mustafa Ekici, Ayşe İlksen Çolpak, Kelly L. Brown, Ömer Karadağ, Banu Balci-Peynircioglu

Erschienen in: Clinical and Experimental Medicine | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

Behçet’s syndrome is a recurring inflammatory multiorgan disorder affecting the skin, mucosa, eyes, joints, stomach, and central nervous system. Behçet’s syndrome epidemiology varies greatly among populations (0.64–420/100,000), and Behçet’s syndrome has gained increasing international acclaim in the recent 50 years due to raising awareness of the syndrome, although it is rare in most population. In addition to the unclear etiology of the syndrome, the diagnosis of Behçet’s syndrome is complicated by a vague clinical presentation, phenotypic heterogeneity and/or incomplete representation, and the lack of any specific laboratory, radiographic, or histological findings. There exists a dire need to elucidate factors that contribute to disease pathogenesis and/or are associated with clinical features of Behçet’s syndrome and the classification of different forms of the syndrome. The identification of such molecular, cellular, and/or clinical factors are crucial for timely diagnosis and efficacious management of Behçet’s syndrome. We discuss recent advances in the clinical diagnosis of Behçet’s syndrome and related contributions of genetics, epigenetics, microbiome, inflammasomes, and autoantibodies to the improved diagnosis, management, and understanding of Behçet’s syndrome.
Literatur
1.
Zurück zum Zitat Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. Behçet’s syndrome: one year in review 2022. Clin Exp Rheumatol. 2022;40(8):1461–71.PubMed Hatemi G, Seyahi E, Fresko I, Talarico R, Uçar D, Hamuryudan V. Behçet’s syndrome: one year in review 2022. Clin Exp Rheumatol. 2022;40(8):1461–71.PubMed
2.
Zurück zum Zitat Hellmich B, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30.PubMed Hellmich B, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2020;79(1):19–30.PubMed
3.
Zurück zum Zitat McHugh J. Different phenotypes identified for Behçet syndrome. Nat Rev Rheumatol. 2021;17(4):188–188.PubMed McHugh J. Different phenotypes identified for Behçet syndrome. Nat Rev Rheumatol. 2021;17(4):188–188.PubMed
4.
Zurück zum Zitat Soejima Y, et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan. Arthritis Res Ther. 2021;23(1):49.PubMedPubMedCentral Soejima Y, et al. Changes in the proportion of clinical clusters contribute to the phenotypic evolution of Behçet’s disease in Japan. Arthritis Res Ther. 2021;23(1):49.PubMedPubMedCentral
5.
Zurück zum Zitat Zou J, et al. Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther. 2021;23(1):45.PubMedPubMedCentral Zou J, et al. Cluster analysis of phenotypes of patients with Behçet’s syndrome: a large cohort study from a referral center in China. Arthritis Res Ther. 2021;23(1):45.PubMedPubMedCentral
6.
Zurück zum Zitat Yazici H, et al. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107–19.PubMed Yazici H, et al. Behçet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14(2):107–19.PubMed
7.
Zurück zum Zitat Kul Cinar O, Romano M, Guzel F, Brogan PA, Demirkaya E. Paediatric Behçet’s disease: a comprehensive review with an emphasis on monogenic mimics. J Clin Med. 2022;11(5):1278.PubMedPubMedCentral Kul Cinar O, Romano M, Guzel F, Brogan PA, Demirkaya E. Paediatric Behçet’s disease: a comprehensive review with an emphasis on monogenic mimics. J Clin Med. 2022;11(5):1278.PubMedPubMedCentral
8.
Zurück zum Zitat Ozguler Y, et al. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology. 2018;57(12):2200–12.PubMed Ozguler Y, et al. Management of major organ involvement of Behçet’s syndrome: a systematic review for update of the EULAR recommendations. Rheumatology. 2018;57(12):2200–12.PubMed
9.
Zurück zum Zitat Mahmoudi M, et al. A comprehensive overview on the genetics of Behçet’s disease. Int Rev Immunol. 2022;41(2):84–106.PubMed Mahmoudi M, et al. A comprehensive overview on the genetics of Behçet’s disease. Int Rev Immunol. 2022;41(2):84–106.PubMed
10.
Zurück zum Zitat Azizlerli G, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–6.PubMed Azizlerli G, et al. Prevalence of Behçet’s disease in Istanbul, Turkey. Int J Dermatol. 2003;42(10):803–6.PubMed
11.
Zurück zum Zitat Yurdakul S, et al. The prevalence of Behçet’s syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15(5):820–2.PubMed Yurdakul S, et al. The prevalence of Behçet’s syndrome in a rural area in northern Turkey. J Rheumatol. 1988;15(5):820–2.PubMed
12.
Zurück zum Zitat Idil A, et al. The prevalence of Behcet’s disease above the age of 10 years The results of a pilot study conducted at the Park Primary Health Care Center in Ankara. Turk Ophthalmic Epidemiol. 2002;9(5):325–31. Idil A, et al. The prevalence of Behcet’s disease above the age of 10 years The results of a pilot study conducted at the Park Primary Health Care Center in Ankara. Turk Ophthalmic Epidemiol. 2002;9(5):325–31.
13.
Zurück zum Zitat Kirino Y, Nakajima H. Clinical and genetic aspects of Behçet’s disease in Japan. Intern Med. 2019;58(9):1199–207.PubMedPubMedCentral Kirino Y, Nakajima H. Clinical and genetic aspects of Behçet’s disease in Japan. Intern Med. 2019;58(9):1199–207.PubMedPubMedCentral
14.
Zurück zum Zitat Muruganandam, M., et al. Characteristics of Behcet's disease in the American Southwest. in Seminars in Arthritis and Rheumatism. 2019. Elsevier. Muruganandam, M., et al. Characteristics of Behcet's disease in the American Southwest. in Seminars in Arthritis and Rheumatism. 2019. Elsevier.
15.
Zurück zum Zitat Tunes RS, et al. Prevalence of Behcet’s syndrome in patients with recurrent aphthous ulcerations in Brazil. Rheumatol Int. 2009;29(8):875–8.PubMed Tunes RS, et al. Prevalence of Behcet’s syndrome in patients with recurrent aphthous ulcerations in Brazil. Rheumatol Int. 2009;29(8):875–8.PubMed
16.
Zurück zum Zitat Fernández-Ávila DG, et al. Prevalence and demographic characteristics of Behcet disease in Colombia: data from the national health registry 2012–2016. Rheumatol Int. 2020;40(1):17–20.PubMed Fernández-Ávila DG, et al. Prevalence and demographic characteristics of Behcet disease in Colombia: data from the national health registry 2012–2016. Rheumatol Int. 2020;40(1):17–20.PubMed
17.
Zurück zum Zitat Maldini C, et al. Exploring the variability in Behçet’s disease prevalence: a meta-analytical approach. Rheumatology. 2018;57(1):185–95.PubMed Maldini C, et al. Exploring the variability in Behçet’s disease prevalence: a meta-analytical approach. Rheumatology. 2018;57(1):185–95.PubMed
18.
Zurück zum Zitat Lin Y-H, et al. Epidemiology of Behcet’s disease in Taiwan: a population-based study. Ophthalmic Epidemiol. 2018;25(4):323–9.PubMed Lin Y-H, et al. Epidemiology of Behcet’s disease in Taiwan: a population-based study. Ophthalmic Epidemiol. 2018;25(4):323–9.PubMed
19.
Zurück zum Zitat Lee Y, et al. Incidence, prevalence, and mortality of Adamantiades-Behçet’s disease in Korea: a nationwide, population-based study (2006–2015). J Eur Acad Dermatol Venereol. 2018;32(6):999–1003.PubMed Lee Y, et al. Incidence, prevalence, and mortality of Adamantiades-Behçet’s disease in Korea: a nationwide, population-based study (2006–2015). J Eur Acad Dermatol Venereol. 2018;32(6):999–1003.PubMed
20.
Zurück zum Zitat Kanecki K, et al. Behcet disease: a rare systemic vasculitis in Poland. Polish Arch Int Med. 2017;127(10):652–6. Kanecki K, et al. Behcet disease: a rare systemic vasculitis in Poland. Polish Arch Int Med. 2017;127(10):652–6.
21.
Zurück zum Zitat Mohammad A, et al. Incidence, prevalence and clinical characteristics of Behcet’s disease in southern Sweden. Rheumatology. 2013;52(2):304–10.PubMed Mohammad A, et al. Incidence, prevalence and clinical characteristics of Behcet’s disease in southern Sweden. Rheumatology. 2013;52(2):304–10.PubMed
22.
Zurück zum Zitat Kappen J, et al. Behçet’s disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth J Med. 2015;73(10):471–7.PubMed Kappen J, et al. Behçet’s disease, hospital-based prevalence and manifestations in the Rotterdam area. Neth J Med. 2015;73(10):471–7.PubMed
23.
Zurück zum Zitat Silman A. Criteria for diagnosis of behcets-disease. Lancet. 1990;335(8697):1078–80. Silman A. Criteria for diagnosis of behcets-disease. Lancet. 1990;335(8697):1078–80.
24.
Zurück zum Zitat Disease ITFTROTICFBS, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47. Disease ITFTROTICFBS, et al. The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.
25.
Zurück zum Zitat Uygunoglu U, Siva A. An uncommon disease included commonly in the differential diagnosis of neurological diseases: Neuro-Behçet’s syndrome. J Neurol Sci. 2021;426:117436.PubMed Uygunoglu U, Siva A. An uncommon disease included commonly in the differential diagnosis of neurological diseases: Neuro-Behçet’s syndrome. J Neurol Sci. 2021;426:117436.PubMed
26.
Zurück zum Zitat Yazici H, Ugurlu S, Seyahi E. Behçet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43(3):275–80.PubMed Yazici H, Ugurlu S, Seyahi E. Behçet syndrome: is it one condition? Clin Rev Allergy Immunol. 2012;43(3):275–80.PubMed
27.
Zurück zum Zitat Group SOUNW. Classification criteria for Behçet disease uveitis. Am J Ophthalmol. 2021;228:80–8. Group SOUNW. Classification criteria for Behçet disease uveitis. Am J Ophthalmol. 2021;228:80–8.
28.
Zurück zum Zitat Tugal-Tutkun I, Onal S, Gül A. Comment on classification criteria for Behçet Disease uveitis. Am J Ophthalmol. 2022;235:336–8.PubMed Tugal-Tutkun I, Onal S, Gül A. Comment on classification criteria for Behçet Disease uveitis. Am J Ophthalmol. 2022;235:336–8.PubMed
29.
Zurück zum Zitat Alibaz-Oner F, et al. Femoral vein wall thickness measurement: A new diagnostic tool for Behçet’s disease. Rheumatol Oxford. 2021;60(1):288–96. Alibaz-Oner F, et al. Femoral vein wall thickness measurement: A new diagnostic tool for Behçet’s disease. Rheumatol Oxford. 2021;60(1):288–96.
30.
Zurück zum Zitat Karadag O, et al. Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. Acta Medica. 2021;52:4–6. Karadag O, et al. Journey of Vasculitis at Hacettepe University: from the Establishment of University to the Hacettepe AAV Workshop, 2020. Acta Medica. 2021;52:4–6.
31.
Zurück zum Zitat Ergun, T., Pathergy phenomenon. Frontiers in medicine, 2021: 637. Ergun, T., Pathergy phenomenon. Frontiers in medicine, 2021: 637.
32.
Zurück zum Zitat Özdemir M, et al. Evaluation of application of multiple needle pricks on the pathergy reaction. Int J Dermatol. 2008;47(4):335–8.PubMed Özdemir M, et al. Evaluation of application of multiple needle pricks on the pathergy reaction. Int J Dermatol. 2008;47(4):335–8.PubMed
33.
Zurück zum Zitat Dilsen N, et al. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis. 1993;52(11):823.PubMedPubMedCentral Dilsen N, et al. Comparative study of the skin pathergy test with blunt and sharp needles in Behcet’s disease: confirmed specificity but decreased sensitivity with sharp needles. Ann Rheum Dis. 1993;52(11):823.PubMedPubMedCentral
34.
Zurück zum Zitat Karadağ AS, et al. Comparison of clinical and histopathologic findings of pathergy test with disposable/sharp and nondisposable/blunt needles in Behcet´ s disease. Turkish J Med Sci. 2009;39(1):47–51. Karadağ AS, et al. Comparison of clinical and histopathologic findings of pathergy test with disposable/sharp and nondisposable/blunt needles in Behcet´ s disease. Turkish J Med Sci. 2009;39(1):47–51.
35.
Zurück zum Zitat Gilhar A, et al. Skin hyperreactivity. response (pathergy) in Behçet’s disease. J Am Acad Dermatol. 1989;21(3):547–52.PubMed Gilhar A, et al. Skin hyperreactivity. response (pathergy) in Behçet’s disease. J Am Acad Dermatol. 1989;21(3):547–52.PubMed
36.
Zurück zum Zitat Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W. Changes in body composition and bone mineral density n postmenopausal women with psoriatic arthritis. Reumatol Rheumatol. 2017;55(5):215–21. Krajewska-Włodarczyk M, Owczarczyk-Saczonek A, Placek W. Changes in body composition and bone mineral density n postmenopausal women with psoriatic arthritis. Reumatol Rheumatol. 2017;55(5):215–21.
37.
Zurück zum Zitat Varol A, Seifert O, Anderson CD. The skin pathergy test: innately useful? Arch Dermatol Res. 2010;302(3):155–68.PubMed Varol A, Seifert O, Anderson CD. The skin pathergy test: innately useful? Arch Dermatol Res. 2010;302(3):155–68.PubMed
38.
Zurück zum Zitat Sasor SE, et al. Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J Wound Care. 2018;27(Sup1):S4–8.PubMed Sasor SE, et al. Pyoderma gangrenosum demographics, treatments, and outcomes: an analysis of 2,273 cases. J Wound Care. 2018;27(Sup1):S4–8.PubMed
39.
Zurück zum Zitat von den Driesch P. Sweet’s syndrome: pathogenesis and associated conditions. J Am Acad Dermatol. 1991;25(3):577–8.PubMed von den Driesch P. Sweet’s syndrome: pathogenesis and associated conditions. J Am Acad Dermatol. 1991;25(3):577–8.PubMed
40.
Zurück zum Zitat Davatchi F, et al. Impact of the positive pathergy test on the performance of classification/diagnosis criteria for Behcet’s disease. Mod Rheumatol. 2013;23(1):125–32.PubMed Davatchi F, et al. Impact of the positive pathergy test on the performance of classification/diagnosis criteria for Behcet’s disease. Mod Rheumatol. 2013;23(1):125–32.PubMed
41.
Zurück zum Zitat Deniz, R., et al., Improved sensitivity of skin pathergy test with polysaccharide pneumococcal vaccine antigens in the diagnosis of Behçet disease. Rheumatology, 2022. Deniz, R., et al., Improved sensitivity of skin pathergy test with polysaccharide pneumococcal vaccine antigens in the diagnosis of Behçet disease. Rheumatology, 2022.
42.
Zurück zum Zitat Shenavandeh S, Sadeghi SMK, Aflaki E. Pathergy test with a 23G needle with and without self-saliva in patients with Behçet’s disease, recurrent aphthous stomatitis and control group compared to the 20G test. Reumatol Rheumatol. 2021;59(1):302–8. Shenavandeh S, Sadeghi SMK, Aflaki E. Pathergy test with a 23G needle with and without self-saliva in patients with Behçet’s disease, recurrent aphthous stomatitis and control group compared to the 20G test. Reumatol Rheumatol. 2021;59(1):302–8.
43.
Zurück zum Zitat de Menthon M, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.PubMed de Menthon M, et al. HLA-B51/B5 and the risk of Behçet’s disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.PubMed
44.
Zurück zum Zitat Dalvi SR, Yildirim R, Yazici Y. Behcet’s syndrome. Drugs. 2012;72(17):2223–41.PubMed Dalvi SR, Yildirim R, Yazici Y. Behcet’s syndrome. Drugs. 2012;72(17):2223–41.PubMed
45.
Zurück zum Zitat Takeno M. The association of Behçet’s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol. 2022;34(1):4–9.PubMed Takeno M. The association of Behçet’s syndrome with HLA-B51 as understood in 2021. Curr Opin Rheumatol. 2022;34(1):4–9.PubMed
46.
Zurück zum Zitat Kirino Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.PubMedPubMedCentral Kirino Y, et al. Genome-wide association analysis identifies new susceptibility loci for Behçet’s disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.PubMedPubMedCentral
47.
Zurück zum Zitat Guasp P, et al. The Peptidome of Behçet’s Disease-associated HLA-B*51:01 includes two subpeptidomes differentially shaped by endoplasmic reticulum aminopeptidase 1. Arthritis Rheumatol. 2016;68(2):505–15.PubMed Guasp P, et al. The Peptidome of Behçet’s Disease-associated HLA-B*51:01 includes two subpeptidomes differentially shaped by endoplasmic reticulum aminopeptidase 1. Arthritis Rheumatol. 2016;68(2):505–15.PubMed
48.
Zurück zum Zitat Takeuchi M, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet’s disease in HLA-B*51 carriers. Ann Rheum Dis. 2016;75(12):2208–11.PubMed Takeuchi M, et al. A single endoplasmic reticulum aminopeptidase-1 protein allotype is a strong risk factor for Behçet’s disease in HLA-B*51 carriers. Ann Rheum Dis. 2016;75(12):2208–11.PubMed
49.
Zurück zum Zitat Guasp P, et al. The Behçet’s disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing. J Biol Chem. 2017;292(23):9680–9.PubMedPubMedCentral Guasp P, et al. The Behçet’s disease-associated variant of the aminopeptidase ERAP1 shapes a low-affinity HLA-B*51 peptidome by differential subpeptidome processing. J Biol Chem. 2017;292(23):9680–9.PubMedPubMedCentral
50.
Zurück zum Zitat Cavers A, et al. Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity. Ann Rheum Dis. 2022;81(11):1603–11.PubMed Cavers A, et al. Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity. Ann Rheum Dis. 2022;81(11):1603–11.PubMed
51.
Zurück zum Zitat Mizuki N, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMed Mizuki N, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet’s disease susceptibility loci. Nat Genet. 2010;42(8):703–6.PubMed
52.
Zurück zum Zitat Remmers EF, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42(8):698–702.PubMedPubMedCentral Remmers EF, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet’s disease. Nat Genet. 2010;42(8):698–702.PubMedPubMedCentral
53.
Zurück zum Zitat Ortiz Fernández L, et al. Genetic association of a gain-of-function IFNGR1 polymorphism and the intergenic region LNCAROD/DKK1 With Behçet’s Disease. Arthritis Rheumatol. 2021;73(7):1244–52.PubMedPubMedCentral Ortiz Fernández L, et al. Genetic association of a gain-of-function IFNGR1 polymorphism and the intergenic region LNCAROD/DKK1 With Behçet’s Disease. Arthritis Rheumatol. 2021;73(7):1244–52.PubMedPubMedCentral
54.
Zurück zum Zitat Manthiram K, et al. Common genetic susceptibility loci link PFAPA syndrome, Behçet’s disease, and recurrent aphthous stomatitis. Proc Natl Acad Sci U S A. 2020;117(25):14405–11.PubMedPubMedCentral Manthiram K, et al. Common genetic susceptibility loci link PFAPA syndrome, Behçet’s disease, and recurrent aphthous stomatitis. Proc Natl Acad Sci U S A. 2020;117(25):14405–11.PubMedPubMedCentral
55.
Zurück zum Zitat Calle-Fabregat CD, Morante-Palacios O, Ballestar E. Understanding the relevance of DNA methylation changes in immune differentiation and disease. Genes. 2020;11(1):110.PubMedPubMedCentral Calle-Fabregat CD, Morante-Palacios O, Ballestar E. Understanding the relevance of DNA methylation changes in immune differentiation and disease. Genes. 2020;11(1):110.PubMedPubMedCentral
56.
Zurück zum Zitat Kolahi S, et al. Evaluation of DNA methylation status of toll-like receptors 2 and 4 promoters in Behcet’s disease. J Gene Med. 2020;22(10):e3234.PubMed Kolahi S, et al. Evaluation of DNA methylation status of toll-like receptors 2 and 4 promoters in Behcet’s disease. J Gene Med. 2020;22(10):e3234.PubMed
57.
Zurück zum Zitat Alipour S, et al. Methylation status of interleukin-6 gene promoter in patients with Behçet’s disease. Reumatol Clín. 2020;16(3):229–34.PubMed Alipour S, et al. Methylation status of interleukin-6 gene promoter in patients with Behçet’s disease. Reumatol Clín. 2020;16(3):229–34.PubMed
58.
Zurück zum Zitat Abdi A, et al. Evaluation of SOCS1 methylation in patients with Behcet’s disease. Immunol Lett. 2018;203:15–20.PubMed Abdi A, et al. Evaluation of SOCS1 methylation in patients with Behcet’s disease. Immunol Lett. 2018;203:15–20.PubMed
59.
Zurück zum Zitat Hughes T, et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behçet’s disease. Arthritis Rheumatol. 2014;66(6):1648–58.PubMedPubMedCentral Hughes T, et al. Epigenome-wide scan identifies a treatment-responsive pattern of altered DNA methylation among cytoskeletal remodeling genes in monocytes and CD4+ T cells from patients with Behçet’s disease. Arthritis Rheumatol. 2014;66(6):1648–58.PubMedPubMedCentral
60.
Zurück zum Zitat Qiu Y, et al. The role of sirtuin-1 in immune response and systemic lupus erythematosus. Front Immunol. 2021;12:632383.PubMedPubMedCentral Qiu Y, et al. The role of sirtuin-1 in immune response and systemic lupus erythematosus. Front Immunol. 2021;12:632383.PubMedPubMedCentral
61.
Zurück zum Zitat Zhang J, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest. 2009;119(10):3048–58.PubMedPubMedCentral Zhang J, et al. The type III histone deacetylase Sirt1 is essential for maintenance of T cell tolerance in mice. J Clin Invest. 2009;119(10):3048–58.PubMedPubMedCentral
62.
Zurück zum Zitat Xie M, Yang Y. Decreased expression of sirt1 contributes to ocular Behçet’s disease progression via Th17 and Th22 response. Ophthalmic Res. 2021;64(4):554–60.PubMed Xie M, Yang Y. Decreased expression of sirt1 contributes to ocular Behçet’s disease progression via Th17 and Th22 response. Ophthalmic Res. 2021;64(4):554–60.PubMed
63.
Zurück zum Zitat O’Brien J, et al. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol Lausanne. 2018;9:402.PubMedPubMedCentral O’Brien J, et al. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol Lausanne. 2018;9:402.PubMedPubMedCentral
64.
65.
Zurück zum Zitat Woo M-Y, et al. MicroRNAs differentially expressed in Behçet disease are involved in interleukin-6 production. J Inflamm. 2016;13(1):22. Woo M-Y, et al. MicroRNAs differentially expressed in Behçet disease are involved in interleukin-6 production. J Inflamm. 2016;13(1):22.
66.
Zurück zum Zitat Emmi G, et al. A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome. Ann Rheum Dis. 2022;81(3):386–97.PubMed Emmi G, et al. A unique circulating miRNA profile highlights thrombo-inflammation in Behçet’s syndrome. Ann Rheum Dis. 2022;81(3):386–97.PubMed
67.
Zurück zum Zitat Ibrahim W, et al. MicroRNA-146a expression and microRNA-146a rs2910164 polymorphism in Behcet’s disease patients. Clin Rheumatol. 2019;38(2):397–402.PubMed Ibrahim W, et al. MicroRNA-146a expression and microRNA-146a rs2910164 polymorphism in Behcet’s disease patients. Clin Rheumatol. 2019;38(2):397–402.PubMed
68.
Zurück zum Zitat Mohammed SR, et al. Expression of lncRNAs NEAT1 and lnc-DC in serum from patients with Behçet’s disease can be used as predictors of disease. Front Mol Biosci. 2021;8:797689.PubMed Mohammed SR, et al. Expression of lncRNAs NEAT1 and lnc-DC in serum from patients with Behçet’s disease can be used as predictors of disease. Front Mol Biosci. 2021;8:797689.PubMed
69.
Zurück zum Zitat Sirisinha S. The potential impact of gut microbiota on your health: current status and future challenges. Asian Pac J Allergy Immunol. 2016;34(4):249–64.PubMed Sirisinha S. The potential impact of gut microbiota on your health: current status and future challenges. Asian Pac J Allergy Immunol. 2016;34(4):249–64.PubMed
70.
Zurück zum Zitat Coit P, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet’s disease. Clin Immunol. 2016;169:28–35.PubMed Coit P, et al. Sequencing of 16S rRNA reveals a distinct salivary microbiome signature in Behçet’s disease. Clin Immunol. 2016;169:28–35.PubMed
71.
72.
Zurück zum Zitat Mumcu G, Fortune F. Oral health and its aetiological role in Behçet’s Disease. Front Med Lausanne. 2021;8:613419.PubMedPubMedCentral Mumcu G, Fortune F. Oral health and its aetiological role in Behçet’s Disease. Front Med Lausanne. 2021;8:613419.PubMedPubMedCentral
73.
Zurück zum Zitat Consolandi C, et al. Behçet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269–76.PubMed Consolandi C, et al. Behçet’s syndrome patients exhibit specific microbiome signature. Autoimmun Rev. 2015;14(4):269–76.PubMed
74.
Zurück zum Zitat Kim JC, Park MJ, Park S, Lee ES. Alteration of the fecal but not salivary microbiome in patients with behcet’s disease according to disease activity shift. Microorganisms. 2021;9(7):1449.PubMedPubMedCentral Kim JC, Park MJ, Park S, Lee ES. Alteration of the fecal but not salivary microbiome in patients with behcet’s disease according to disease activity shift. Microorganisms. 2021;9(7):1449.PubMedPubMedCentral
75.
Zurück zum Zitat van der Houwen TB, et al. Behçet’s disease under microbiotic surveillance? A combined analysis of two cohorts of Behçet’s disease patients. Front Immunol. 2020;11:1192.PubMedPubMedCentral van der Houwen TB, et al. Behçet’s disease under microbiotic surveillance? A combined analysis of two cohorts of Behçet’s disease patients. Front Immunol. 2020;11:1192.PubMedPubMedCentral
76.
Zurück zum Zitat Emmi G, et al. Butyrate-rich diets improve redox status and fibrin lysis in Behçet’s syndrome. Circ Res. 2021;128(2):278–80.PubMed Emmi G, et al. Butyrate-rich diets improve redox status and fibrin lysis in Behçet’s syndrome. Circ Res. 2021;128(2):278–80.PubMed
77.
Zurück zum Zitat Navarro M, et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus. 1997;6(6):521–6.PubMed Navarro M, et al. Anti-endothelial cell antibodies in systemic autoimmune diseases: prevalence and clinical significance. Lupus. 1997;6(6):521–6.PubMed
78.
Zurück zum Zitat Zheng W, et al. A study of antiendothelial cell antibodies in Behcet’s disease. Zhonghua Nei Ke Za Zhi. 2005;44(12):910–3.PubMed Zheng W, et al. A study of antiendothelial cell antibodies in Behcet’s disease. Zhonghua Nei Ke Za Zhi. 2005;44(12):910–3.PubMed
79.
Zurück zum Zitat Souza RC, et al. Anti-endothelial cell antibodies and central nervous system involvement in Behçet’s disease. Clinics. 2007;62:685–90.PubMed Souza RC, et al. Anti-endothelial cell antibodies and central nervous system involvement in Behçet’s disease. Clinics. 2007;62:685–90.PubMed
80.
Zurück zum Zitat Lee KH, et al. Human α-enolase from endothelial cells as a target antigen of anti–endothelial cell antibody in Behçet’s disease. Arthritis Rheum Off J Am College Rheumatol. 2003;48(7):2025–35. Lee KH, et al. Human α-enolase from endothelial cells as a target antigen of anti–endothelial cell antibody in Behçet’s disease. Arthritis Rheum Off J Am College Rheumatol. 2003;48(7):2025–35.
81.
Zurück zum Zitat Kang SE, Lee SJ, Lee JY, Yoo HJ, Park JK, Lee EY, Lee EB, Song YW. Serum levels of IgG antibodies against alpha-enolase are increased in patients with Behçet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates, and C-reactive protein. Clin Exp Rheumatol. 2017;35(6):67–74.PubMed Kang SE, Lee SJ, Lee JY, Yoo HJ, Park JK, Lee EY, Lee EB, Song YW. Serum levels of IgG antibodies against alpha-enolase are increased in patients with Behçet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates, and C-reactive protein. Clin Exp Rheumatol. 2017;35(6):67–74.PubMed
82.
Zurück zum Zitat Direskeneli H, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet’s disease. Clin Rheumatol. 1995;14(1):55–61.PubMed Direskeneli H, et al. Anti-endothelial cell antibodies, endothelial proliferation and von Willebrand factor antigen in Behçet’s disease. Clin Rheumatol. 1995;14(1):55–61.PubMed
83.
Zurück zum Zitat Hussain M, et al. Moesin expression is correlated with its involvement in patients with Behcet’s disease. Arch Med Sci. 2020;16(4):924–30.PubMedPubMedCentral Hussain M, et al. Moesin expression is correlated with its involvement in patients with Behcet’s disease. Arch Med Sci. 2020;16(4):924–30.PubMedPubMedCentral
84.
Zurück zum Zitat Delunardo F, et al. Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behçet’s disease. Arthritis Res Ther. 2006;8(3):R71.PubMedPubMedCentral Delunardo F, et al. Identification and characterization of the carboxy-terminal region of Sip-1, a novel autoantigen in Behçet’s disease. Arthritis Res Ther. 2006;8(3):R71.PubMedPubMedCentral
85.
Zurück zum Zitat Kang SE, et al. Serum levels of IgG antibodies against alpha-enolase are increased in patients with Behcet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates, and C-reactive protein. Clin Exp Rheumatol. 2017;35(6):67–74.PubMed Kang SE, et al. Serum levels of IgG antibodies against alpha-enolase are increased in patients with Behcet’s disease and are associated with the severity of oral ulcer, erythrocyte sedimentation rates, and C-reactive protein. Clin Exp Rheumatol. 2017;35(6):67–74.PubMed
86.
Zurück zum Zitat Cho SB, et al. Identification of HnRNP-A2/B1 as a target antigen of anti-endothelial cell IgA antibody in Behçet’s disease. J Invest Dermatol. 2012;132(3 Pt 1):601–8.PubMed Cho SB, et al. Identification of HnRNP-A2/B1 as a target antigen of anti-endothelial cell IgA antibody in Behçet’s disease. J Invest Dermatol. 2012;132(3 Pt 1):601–8.PubMed
87.
Zurück zum Zitat Hu CJ, et al. Identification of novel biomarkers for behcet disease diagnosis using human proteome microarray approach. Mol Cell Proteomics. 2017;16(2):147–56.PubMed Hu CJ, et al. Identification of novel biomarkers for behcet disease diagnosis using human proteome microarray approach. Mol Cell Proteomics. 2017;16(2):147–56.PubMed
88.
Zurück zum Zitat Xun Y, et al. Identification of prohibitin as an antigen in Behcet’s disease. Biochem Biophys Res Commun. 2014;451(3):389–93.PubMed Xun Y, et al. Identification of prohibitin as an antigen in Behcet’s disease. Biochem Biophys Res Commun. 2014;451(3):389–93.PubMed
89.
Zurück zum Zitat Cheng Y, et al. Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet’s Disease. PLoS ONE. 2018;13(6):e0199047.PubMedPubMedCentral Cheng Y, et al. Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet’s Disease. PLoS ONE. 2018;13(6):e0199047.PubMedPubMedCentral
90.
Zurück zum Zitat Rojas M, et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100–23.PubMed Rojas M, et al. Molecular mimicry and autoimmunity. J Autoimmun. 2018;95:100–23.PubMed
91.
Zurück zum Zitat Lule S, et al. Behçet Disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun. 2017;84:87–96.PubMed Lule S, et al. Behçet Disease serum is immunoreactive to neurofilament medium which share common epitopes to bacterial HSP-65, a putative trigger. J Autoimmun. 2017;84:87–96.PubMed
92.
Zurück zum Zitat Malcova H, et al. Interleukin-1 blockade in polygenic autoinflammatory disorders: where are we now? Front Pharmacol. 2020;11:619273.PubMed Malcova H, et al. Interleukin-1 blockade in polygenic autoinflammatory disorders: where are we now? Front Pharmacol. 2020;11:619273.PubMed
93.
Zurück zum Zitat Emmi G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–6.PubMed Emmi G, et al. Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study. Clin Rheumatol. 2016;35(5):1281–6.PubMed
94.
Zurück zum Zitat Kim EH, et al. Increased expression of the NLRP3 inflammasome components in patients with Behçet’s disease. J Inflamm. 2015;12(1):41. Kim EH, et al. Increased expression of the NLRP3 inflammasome components in patients with Behçet’s disease. J Inflamm. 2015;12(1):41.
95.
Zurück zum Zitat Hamzaoui K, et al. Elevated levels of IL-32 in cerebrospinal fluid of neuro-Behcet disease: Correlation with NLRP3 inflammasome. J Neuroimmunol. 2022;365:577820.PubMed Hamzaoui K, et al. Elevated levels of IL-32 in cerebrospinal fluid of neuro-Behcet disease: Correlation with NLRP3 inflammasome. J Neuroimmunol. 2022;365:577820.PubMed
96.
Zurück zum Zitat Faghfouri AH, et al. Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial. Int Immunopharmacol. 2022;109:108825.PubMed Faghfouri AH, et al. Regulation of NLRP3 inflammasome by zinc supplementation in Behçet’s disease patients: A double-blind, randomized placebo-controlled clinical trial. Int Immunopharmacol. 2022;109:108825.PubMed
97.
Zurück zum Zitat Park YH, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17(8):914–21.PubMedPubMedCentral Park YH, et al. Pyrin inflammasome activation and RhoA signaling in the autoinflammatory diseases FMF and HIDS. Nat Immunol. 2016;17(8):914–21.PubMedPubMedCentral
98.
Zurück zum Zitat Touitou I, et al. MEFV mutations in Behçet’s disease. Hum Mutat. 2000;16(3):271–2.PubMed Touitou I, et al. MEFV mutations in Behçet’s disease. Hum Mutat. 2000;16(3):271–2.PubMed
99.
Zurück zum Zitat Burillo-Sanz S, et al. Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A next generation sequencing approach. Sci Rep. 2017;7(1):8453.PubMedPubMedCentral Burillo-Sanz S, et al. Mutational profile of rare variants in inflammasome-related genes in Behçet disease: A next generation sequencing approach. Sci Rep. 2017;7(1):8453.PubMedPubMedCentral
100.
Zurück zum Zitat Aydıntug A, et al. Antibodies to endothelial cells in patients with Behçet’s disease. Clin Immunol Immunopathol. 1993;67(2):157–62.PubMed Aydıntug A, et al. Antibodies to endothelial cells in patients with Behçet’s disease. Clin Immunol Immunopathol. 1993;67(2):157–62.PubMed
Metadaten
Titel
Behçet’s syndrome: recent advances to aid diagnosis
verfasst von
Tayfun Hilmi Akbaba
Mustafa Ekici
Ayşe İlksen Çolpak
Kelly L. Brown
Ömer Karadağ
Banu Balci-Peynircioglu
Publikationsdatum
28.10.2023
Verlag
Springer International Publishing
Erschienen in
Clinical and Experimental Medicine / Ausgabe 8/2023
Print ISSN: 1591-8890
Elektronische ISSN: 1591-9528
DOI
https://doi.org/10.1007/s10238-023-01226-7

Weitere Artikel der Ausgabe 8/2023

Clinical and Experimental Medicine 8/2023 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.